NewAmsterdam Pharma (NAMS) Operating Income (2023 - 2026)

NewAmsterdam Pharma has disclosed Operating Income across 4 years of filings, most recently posting -$58.4 million for Q1 2026.

• Operating Income for Q1 2026 came in at -$58.4 million, up 15.24% year-over-year; the trailing twelve-month figure through Mar 2026 was -$215.2 million (down 13.41% YoY), and the FY2025 annual result was -$225.7 million, down 28.02% from the prior year.
• Operating Income came in at -$58.4 million for Q1 2026 at NewAmsterdam Pharma, up from -$66.0 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$25.0 million in Q3 2024 to a low of -$68.9 million in Q1 2025.
• The 4-year median for Operating Income is -$51.1 million (2023), against an average of -$49.5 million.
• Across the five-year window, Operating Income jumped 49.55% in 2024 and sank 120.55% in 2025, its largest moves.
• NewAmsterdam Pharma's Operating Income stood at -$51.1 million in 2023, then rose by 15.36% to -$43.2 million in 2024, then sank by 52.63% to -$66.0 million in 2025, then gained by 11.46% to -$58.4 million in 2026.
• The last three Operating Income figures came in at -$58.4 million (Q1 2026), -$66.0 million (Q4 2025), and -$55.1 million (Q3 2025), per Business Quant data.